Insight

At a crossroads, Ironwood CEO Peter Hecht maps a big leap forward

"We want to build a standalone, great pharmaceutical company. The ambition isn't size, it’s quality and making drugs that really matter.” — Peter Hecht, Ironwood, 2009.

First-in-class "GlycoCAR" works for solid tumors and leukemia

First-in-class "GlycoCAR" works for solid tumors and leukemia


Jul 21, 2016

A new anticancer immunotherapy using chimeric antigen receptor (CAR) T-cells has been developed at University of Pennsylvania, targeting tumors as well as blood-borne cancer cells.

AZ BioVentureHub CEO says aim is an innovative ecosystem

AZ BioVentureHub CEO says aim is an innovative ecosystem


Jun 21, 2016

AstraZeneca’s BioVentureHub CEO explains the exchange's vision to generate a climate of open innovation to help grow and nurture the Scandinavian life science ecosystem.

partnering360®: leverage and cultivate your dealmaker network

partnering360 is the network for dealmakers in the life science industry. This global community of more than 34,000 is constantly growing, and the partnering opportunities continually updating.